PCM
GTHX

Penserra Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Penserra Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-965
Closed -$12K – 1590
2021
Q3 		$12K Buy
965
+5
+0.5% +$81 ﹤0.01% 1338
2021
Q2 		$21K Buy
960
+15
+2% +$333 ﹤0.01% 1140
2021
Q1 		$22K Buy
945
+70
+8% +$1.63K ﹤0.01% 962
2020
Q4 		$15K Buy
875
+551
+170% +$8.23K ﹤0.01% 888
2020
Q3 		$3K Buy
+324
New +$5.35K ﹤0.01% 894

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Penserra Capital Management's GTHX Position: Q4 2021 in Review

Penserra Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 965 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in GTHX in Q3 2020 and held it in 5 quarters. The position peaked at $22K in Q1 2021. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

  • Penserra Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 965 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $12K.
  • Penserra Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $22K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.